Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 12, 2012, Pages 7484-7491

  Kauper, Konrad ^a   McGovern, Cahil ^a   Sherman, Sandy ^a   Heatherton, Pam ^a   Rapoza, Rob ^a   Stabila, Paul ^a   Dean, Brenda ^a   Lee, Alice ^a   Borges, Suzanna ^a   Bouchard, Bruce ^a   Tao, Weng ^a  

^a Neurotech Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CILIARY NEUROTROPHIC FACTOR; CIPROFLOXACIN; PREDNISOLONE ACETATE;

ARTICLE; CELL ENCAPSULATION; CELL VIABILITY; CONTROLLED STUDY; DRUG HALF LIFE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLANT; GEOGRAPHIC ATROPHY; HUMAN; HUMAN TISSUE; IMMUNITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; OPHTHALMOLOGICAL IMPLANT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETINITIS PIGMENTOSA; RETROSPECTIVE STUDY; VITREOUS BODY;

CHRONIC DISEASE; CILIARY NEUROTROPHIC FACTOR; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; RETINA; RETINAL DEGENERATION; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84868321731     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9970     Document Type: Article

References (34)

1. McDonald NQ, Panayotatos N, Hendrickson WA. Crystal structure of dimeric human ciliary neurotrophic factor determined by MAD phasing. EMBO J. 1995;14:2689-2699.
2. Panayotatos N, Radziejewska E, Acheson A, et al. Localization of functional receptor epitopes on the structure of ciliary neurotrophic factor indicates a conserved, funtion-related epitope topography among helical cytokines. J Biol Chem. 1995;270:14007-14014.
3. Stahl N, Yancopoulos GD. The tripartite CNTF receptor complex: Activation and signaling involves components shared with other cytokines. J Neurobiol. 1994;25:1454-1466.
4. Beltran W, Allore H, Johnson E, et al. CREB1/ATF1 Activation in photoreceptor degeneration and protection. Invest Ophthalmol Vis Sci. 2009;50:5355-5363.
5. LaVail MM, Yasumura D, Matthes MT et al. Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest Ophthalmol Vis Sci. 1998;39:592-602.
6. Cayouette M, Gravel C. Adenovirus-mediated gene transfer of ciliary neurotrophic factor can prevent photoreceptor degeneration in the retinal degeneration (rd) mouse. Hum Gene Ther. 1997;8:423-430.
7. LaVail MM, Unoki K, Yasumuri D, Matthes MT, Yancopoulos GD, Steinberg RH. Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of contant light. Proc Nat Acad Sci U S A. 1992;89: 11249-11253.
8. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. The pharmacokinetics of subcutaneously administered recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis: Relation to parameters of the acute-phase response. Clin Neurophamacol. 1995;18: 500-514.
9. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12:348-360.
10. Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res. 1996;62:155-169.
11. Heath C, Kiss R. Cell culture process development: advances in process engineering. Biotechnol Prog. 2007;23:46-51.
12. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New Engl J Med. 2011;364:1897-1908.
13. Dittrich F, Thoenen H, Sendtner M. Ciliary neurotrophic factor: pharmacokinetics and the acute-phase response in rat. Ann Neurol. 1994;35:151-163.
14. Beltran W, Wen R, Acland G, Aguirre G. Intravitreal injection of ciliary neurotrophic factor (CNTF) causes peripheral remodeling and does not prevent photoreceptor loss in canine RPGR mutant retina. Exp Eye Res. 2007;84:753-771.
15. Limm LL, Smith JR, Rosenbaum JT. Retisert (Bausch & Lomb/Control Delivery Systems). Curr Opin Investig Drugs. 2005;6: 1159-67.
16. Cadman J. Ganciclovir implants: one year later. GMHC Treat Issues. 1997;11:3-6.
17. Jaffe G, Yang CH, Guo H, Denny J, Lima C, Safety Ashton P. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci. 2000;41:3569-3575.
18. El Sanharawi M, Kowalczuk L, Touchard E, Omri S, de Kozak Y, Behar-Cohen F. Protein delivery for retinal diseases: from basic considerations to clinical applications. Prog Retin Eye Res. 2010;29:443-465.
19. Bok D, Yasumura D, Matthes MT, et al. Effects of adenoassociated virus-vectored ciliary neurotrophic factor on retinal structure and function in mice with a P216L rds/peripherin mutation. Exp Eye Res. 2002;74:719-735.
20. Lee SS, Robinson MR. Novel drug delivery systems for retinal diseases. A review. Ophthalmic Res. 2009;41:124-135.
21. Sieving PA, Caruso R, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc National Acad Sci U S A. 2006;103:3896-3901.
22. Tao W, Wen R, Goddard MB, et al. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2002;43:3292-3298.
23. Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108:6241-6245.
24. Talcott K, Ratnam K, Sundquist S, et al. Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment. Invest Ophthalmol Vis Sci. 2011;52:2219-2226.
25. Cayoutte M, Behn D, Snedtner M, Lachapelle P, Gravel C. Intraocular gene transfer of ciliary neurotrophic factor prevents death and increases responsiveness of rod photoreceptors in the retinal degeneration slow mouse. J Neurosci. 1998;18:9282-9293.
26. Arshinoff S, Opalinski Y, Ma J. The lens. In: Duker J, Yanoff M. Ophthalmology. London, UK: Mosby International; 1999.
27. Aguirre G, Farber D, Lolley R, et al. Retinal degeneration in the dog. III: abnormal cyclic nucleotide metabolism in rod-cone dysplasia. Exp Eye Res. 1982;35:625-642.
28. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology. 2005;112:1048-1053.
29. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. New Engl J Med. 2004;351:2805-2816.
30. Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003; 195:241-248.
31. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92:10457-10461.
32. Brodski C, Vogt Weisenhorn DM, Dechant G. Therapy of neurodegenerative diseases using neurotrophic factors: cell biological perspective. Expert Rev Neurother. 2002;2:417-426.
33. Emerich DF, Winn SR, Hantraye PM, et al. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature. 1997;386: 395-399.
34. Wurm F. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004;22:1393-1398.